Paper24656178
Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy.
Scheffer HJ and 9 others. J Vasc Interv Radiol, 2014. Cited by 302 papers, by iCite.
Cite this record
ConductScience Library. Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. Papers, record 24656178. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24656178
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Ablation Techniques | Major topic |
| Electrochemotherapy | Major topic |
| Neoplasms | Major topic |
| Diffusion Magnetic Resonance Imaging | |
| Humans | |
| Multimodal Imaging | |
| Positron-Emission Tomography | |
| Postoperative Complications | |
| Predictive Value of Tests | |
| Risk Factors | |
| Time Factors | |
| Tomography, X-Ray Computed | |
| Treatment Outcome |
Source PubMed
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT04276857 | Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer | Background | ClinicalTrials.gov | |
| NCT07782164 | Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study) | Background | ClinicalTrials.gov |
Cited by175
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 302 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42905914 | Biophysical principles of pulsed field ablation. | Europace | 2026 | https://conductscience.org/library/papers/42905914 | PubMed |
| 42824129 | Compound steep-pulse irreversible electroporation for prostate ablation in Beagle dogs: parameter evaluation and short-term safety. | Front Urol | 2026 | https://conductscience.org/library/papers/42824129 | PubMed |
| 42779964 | Case Report: Late repeat pancreatic irreversible electroporation in the long-term multidisciplinary management of unresectable pancreatic ductal adenocarcinoma. | Front Oncol | 2026 | https://conductscience.org/library/papers/42779964 | PubMed |
| 42778637 | Irreversible Electroporation for Colorectal Liver Metastases: Long-term Outcomes from a Transatlantic Multicenter Study. | Cardiovasc Intervent Radiol | 2026 | https://conductscience.org/library/papers/42778637 | PubMed |
| 42688057 | Does tumor location affect irreversible electroporation outcomes in pancreatic cancer? A head-to-head comparative cohort study. | Front Oncol | 2026 | https://conductscience.org/library/papers/42688057 | PubMed |
| 42637830 | Safety and Efficacy of an Irreversible Electroporation System with Real-Time Electrical and Thermal Monitoring for Liver Tumors: A Bicentric Retrospective Study. | Cardiovasc Intervent Radiol | 2026 | https://conductscience.org/library/papers/42637830 | PubMed |
| 42627535 | Incidence and risk factors of complications following microsecond and nanosecond pulsed electric field ablation for hepatocellular carcinoma: a 10-year multicenter cohort study. | Eur Radiol | 2026 | https://conductscience.org/library/papers/42627535 | PubMed |
| 42614700 | Electricity-Based Locoregional Cancer Therapies and Their Associated Drug Delivery Technologies: From Principles of Action to Clinical Implications. | Biomater Res | 2026 | https://conductscience.org/library/papers/42614700 | PubMed |
| 42504355 | Irreversible Electroporation Versus Radiofrequency Ablation for Hepatic Malignancies: A Systematic Review and Meta-Analysis. | Cureus | 2026 | https://conductscience.org/library/papers/42504355 | PubMed |
| 42382132 | Efficacy and safety of multiple treatments for small hepatocellular carcinoma: an updated systematic review and component network meta analysis. | EClinicalMedicine | 2026 | https://conductscience.org/library/papers/42382132 | PubMed |
| 42369083 | Biomimetic Nanogels Programmed for Irreversible-Electroporation-Primed Tumor Microenvironments to Elicit Durable Antitumor Immunity. | Biomater Res | 2026 | https://conductscience.org/library/papers/42369083 | PubMed |
| 42018500 | High-intensity irreversible electroporation targeting intracellular structures enhance tumor ablation in lung cancer models. | PLoS One | 2026 | https://conductscience.org/library/papers/42018500 | PubMed |
| 41908232 | Irreversible electroporation for localized prostate cancer: risk-stratified oncologic outcomes and functional preservation. | Prostate Int | 2026 | https://conductscience.org/library/papers/41908232 | PubMed |
| 41729480 | Stereotactic two-needle irreversible electroporation of liver tumors near critical structures: a proof-of-concept study. | Eur Radiol Exp | 2026 | https://conductscience.org/library/papers/41729480 | PubMed |
| 41295487 | In Situ Vaccination by Tumor Ablation: Principles and Prospects for Systemic Antitumor Immunity. | Vaccines (Basel) | 2025 | https://conductscience.org/library/papers/41295487 | PubMed |
| 41070061 | Application of a new coaxial bipolar electrode for the treatment of vertebral metastases: a pilot study in an ovine model. | Front Med (Lausanne) | 2025 | https://conductscience.org/library/papers/41070061 | PubMed |
| 40851065 | Real-world safety of irreversible electroporation therapy for tumors with nanoknife: MAUDE database analysis. | BMC Surg | 2025 | https://conductscience.org/library/papers/40851065 | PubMed |
| 40794619 | Management of liver metastases from uveal melanoma. | Br J Surg | 2025 | https://conductscience.org/library/papers/40794619 | PubMed |
| 40674565 | Electrical Stimulation of Cells: Drivers, Technology, and Effects. | Chem Rev | 2025 | https://conductscience.org/library/papers/40674565 | PubMed |
| 40630200 | Evaluating the immune response in a murine cancer model between irreversible electroporation and an advanced biphasic pulsed electric field technology. | Front Oncol | 2025 | https://conductscience.org/library/papers/40630200 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/24656178
GET https://conductscience.org/api/papers/v1/24656178/cited_by?page=2